Takeda Pharmaceutical (TAK) Accounts Payables: 2018-2025

Historic Accounts Payables for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $3.1 billion.

  • Takeda Pharmaceutical's Accounts Payables fell 15.63% to $3.1 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $3.1 billion, marking a year-over-year decrease of 15.63%. This contributed to the annual value of $3.1 billion for FY2025, which is 17.77% down from last year.
  • As of FY2025, Takeda Pharmaceutical's Accounts Payables stood at $3.1 billion, which was down 17.77% from $3.8 billion recorded in FY2024.
  • Takeda Pharmaceutical's Accounts Payables' 5-year high stood at $4.8 billion during FY2023, with a 5-year trough of $3.1 billion in FY2025.
  • Its 3-year average for Accounts Payables is $3.9 billion, with a median of $3.8 billion in 2024.
  • Per our database at Business Quant, Takeda Pharmaceutical's Accounts Payables surged by 41.78% in 2022 and then fell by 21.00% in 2024.
  • Takeda Pharmaceutical's Accounts Payables (Yearly) stood at $3.2 billion in 2021, then spiked by 41.78% to $4.6 billion in 2022, then increased by 4.50% to $4.8 billion in 2023, then declined by 21.00% to $3.8 billion in 2024, then decreased by 17.77% to $3.1 billion in 2025.